#	Pagina
attuale pagina	/open-h2020/projects/216323/index.html
-1	/open-h2020/projects/203515/index.html
-2	/open-h2020/projects/197575/index.html
-3	/open-h2020/per-topic/ntar/list/index.html

Opendata, web and dolomites

B2B SIGNED

Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

B2B project word cloud

Explore the words cloud of the B2B project. It provides you a very rough idea of what is the project "B2B" about.

device context newly hierarchically hits capillary hurdle patient closed self woman nor composition transcend longitudinally generate limitations ossicles hierarchical branched patients circuit complexity endothelial containing metastatic vascularized tree site physiological comprising metastasis spontaneous overcome fold repurposing passing throughput date cancer drugs breast connected assembled tumor cell structure million dissect macro pursue b2b bone first model technologies continuum identification propagate single size dimensions networks breakthrough screening recapitulate barrier bioprinted vitro agents therapies lack found suppressing linked drug organoids cells clinically hybrid micro ossicle mortality marrow consequently tissue vascular dynamics ones incurable empower 3d spanning disease circulating spread

Project "B2B" data sheet

The following table provides information about the project.

Coordinator	CONSIGLIO NAZIONALE DELLE RICERCHE Organization address address: PIAZZALE ALDO MORO 7 city: ROMA postcode: 185 website: www.cnr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.b2bproject.eu
Total cost	3˙799˙371 €
EC max contribution	3˙799˙371 € (100%)
Programme	1. H2020-EU.1.2.1. (FET Open)
Code Call	H2020-FETOPEN-1-2016-2017
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-07-01 to 2022-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CONSIGLIO NAZIONALE DELLE RICERCHE CONSIGLIO NAZIONALE DELLE RICERCHE Organization address address: PIAZZALE ALDO MORO 7 city: ROMA postcode: 185 website: www.cnr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	coordinator	711˙887.00
2	UNIVERSITAT BASEL UNIVERSITAT BASEL Organization address address: PETERSPLATZ 1 city: BASEL postcode: 4051 website: www.unibas.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BASEL)	participant	1˙198˙345.00
3	UNIVERSITEIT MAASTRICHT UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	464˙383.00
4	REACT4LIFE SRL REACT4LIFE SRL Organization address address: VIA DOMENICO FIASELLA 1 city: GENOVA postcode: 16121 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (GENOVA)	participant	406˙600.00
5	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	390˙825.00
6	CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED Organization address address: ST JOHN'S INNOVATION CENTRE COWLEY ROAD city: CAMBRIDGE postcode: CB4 0WS website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	234˙242.00
7	IN SRL IN SRL Organization address address: VIA CARDUCCI 9A city: UDINE postcode: 33100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (UDINE)	participant	230˙587.00
8	BIOEMISSION TECHNOLOGY SOLUTIONS IKE BIOEMISSION TECHNOLOGY SOLUTIONS IKE Organization address address: ALEXANDRAS AVENUE 116 city: ATHINA postcode: 114 72 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EL (ATHINA)	participant	162˙500.00

Map

Project objective

Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

Deliverables

List of deliverables.
Website and logo	Websites, patent fillings, videos etc.	2019-10-08 17:12:39

Take a look to the deliverables list in detail: detailed list of B2B deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Francesc Castro-Giner, Sofia Gkountela, Cinzia Donato, Ilaria Alborelli, Luca Quagliata, Charlotte Ng, Salvatore Piscuoglio, Nicola Aceto Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations published pages: 31, ISSN: 2075-4418, DOI: 10.3390/diagnostics8020031	Diagnostics 8/2	2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "B2B" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "B2B" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

EggSorter (2019)

Device and method for automatized egg cell inspection and sorting

SHERO (2019)

Self-HEaling soft RObotics

PANACHE (2020)

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.